![logo](/logos/BOLT.webp)
Bolt Biotherapeutics, Inc.
NASDAQ:BOLT
0.65 (USD) • At close September 6, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Bolt Biotherapeutics, Inc. |
Symbool | BOLT |
Munteenheid | USD |
Prijs | 0.648 |
Beurswaarde | 24,780,284 |
Dividendpercentage | 0% |
52-weken bereik | 0.641 - 1.56 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Randall C. Schatzman Ph.D. |
Website | https://www.boltbio.com |
An error occurred while fetching data.
Over Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc., a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)